More recently, combined therapies including the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib and the Bcl-2 inhibitor venetoclax, with or without anti-CD20 monoclonal antibodies (mAbs), have shown promising results in high-risk and older patients with CLL, although an extended follow-up of the trials to assess long-term outcomes has not been done [8,9,10]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.